Table 3 Incidence of related adverse events by system organ class preferred term and NCI-CTCAE grade, safety population. No grade 4 or 5 adverse events observed in part 2.

Cardiac disorders

Tachycardia

AdAPT-001 1 × 10¹² VP

0 (0.0)

1 (5.3)

0 (0.0)

1 (5.3)

Gastrointestinal disorders

Dry mouth

AdAPT-001 1 × 10¹² VP

1 (5.3)

0 (0.0)

0 (0.0)

1 (5.3)

Nausea

AdAPT-001 1 × 10¹² VP

0 (0.0)

1 (5.3)

0 (0.0)

1 (5.3)

Vomiting

AdAPT-001 1 × 10¹² VP

1 (5.3)

0 (0.0)

0 (0.0)

1 (5.3)

General disorders and administration site conditions

Asthenia

AdAPT-001 1 × 10¹² VP

1 (5.3)

0 (0.0)

0 (0.0)

1 (5.3)

Chills

AdAPT-001 1 × 10¹² VP

5 (26.3)

1 (5.3)

0 (0.0)

6 (31.6)

Fatigue

AdAPT-001 1 × 10¹² VP

1 (5.3)

1 (5.3)

0 (0.0)

2 (10.5)

Injection related reaction

AdAPT-001 1 × 10¹² VP

5 (26.3)

0 (0.0)

0 (0.0)

5 (26.3)

Pyrexia

AdAPT-001 1 × 10¹² VP

2 (10.5)

1 (5.3)

0 (0.0)

3 (15.8)

Swelling face

AdAPT-001 1 × 10¹² VP

1 (5.3)

0 (0.0)

0 (0.0)

1 (5.3)

Infections and infestations

Sinusitis

AdAPT-001 1 × 10¹² VP

1 (5.3)

0 (0.0)

0 (0.0)

1 (5.3)

Injury, poisoning, and procedural complications

Injection related reaction

AdAPT-001 1 × 10¹² VP

2 (10.5)

1 (5.3)

0 (0.0)

3 (15.8)

Investigations

Platelet count decreased

AdAPT-001 1 × 10¹² VP

1 (5.3)

0 (0.0)

0 (0.0)

1 (5.3)

Musculoskeletal and connective tissue disorders

Arthralgia

AdAPT-001 1 × 10¹² VP

1 (5.3)

0 (0.0)

0 (0.0)

1 (5.3)

Neck pain

AdAPT-001 1 × 10¹² VP

1 (5.3)

0 (0.0)

0 (0.0)

1 (5.3)

Pain in extremity

AdAPT-001 1 × 10¹² VP

1 (5.3)

0 (0.0)

0 (0.0)

1 (5.3)

Nervous system disorders

Dysgeusia

AdAPT-001 1 × 10¹² VP

1 (5.3)

0 (0.0)

0 (0.0)

1 (5.3)

Skin and subcutaneous tissues disorders

Dermatitis acneiform

AdAPT-001 1 × 10¹² VP

0 (0.0)

0 (0.0)

1 (5.3)

1 (5.3)

Vascular disorders

Hypertension

AdAPT-001 1 × 10¹² VP

0 (0.0)

0 (0.0)

1 (5.3)

1 (5.3)